18F-mFBG PET imaging of heart nerve uptake in Lewy body dementia and Parkinson disease.

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 2, single-site study uses the PET radiotracer 18F-mFBG to quantify myocardial sympathetic innervation in adults with Lewy body disease and in a comparison group with non-Lewy neurological diseases. Clinically stable participants will receive 18F-mFBG and undergo cardiac PET imaging to measure myocardial uptake and clearance parameters. Results from Lewy body and non-Lewy cohorts will be compared with each other and with historical healthy-control data to identify quantitative differences in tracer uptake. The protocol aims to provide more standardized and higher-resolution quantitative measures than traditional 123I-mIBG SPECT methods.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* 1\. ≥18 years of age at study entry. 2. Able and willing to comply with study procedures and signed and dated informed consent is obtained.

  3\. A male or a female who is either surgically sterile (has had a documented bilateral oophorectomy and/or hysterectomy), postmenopausal (cessation of menses for more than 1 year), non-lactating, or of childbearing potential for whom the result of a serum pregnancy test performed at screening is negative.

  4\. All subjects: Judged clinically stable for at least 30 days before enrolment into the study and remains stable to the time of the study imaging procedure.

For Lewy body disease subjects (Study Cohort I):

5\. The subject has a diagnosis of either PD or DLB based on accepted clinical criteria at least 6 months before enrollment into the study.

For non-Lewy body disease subjects (Study Cohort II):

6\. The subject has a diagnosis of neurological or neurodegenerative disease for which neither PD nor DLB is judged likely by a neurologist based on accepted clinical and imaging criteria.

Exclusion Criteria:

* 1\. Previously entered into this study or has participated in any other investigational product or medical device study within 30 days of enrollment.

  2\. History or suspicion of significant allergic reaction or anaphylaxis to any components of the 18F-mFBG imaging agent.

  3\. Presents with any other clinically active, serious, life-threatening disease with a life expectancy of less than 1 year or where participation in the study might compromise the management of the subject or other reason that in the judgment of the investigator(s) makes the subject unsuitable for participation in the study.

  4\. Documented ischemic heart disease (prior myocardial infarction, unstable angina, etc) or a diagnosis of heart failure of ischemic or non-ischemic etiology.

  5\. Serious non-cardiac medical condition associated with significant elevation of plasma catecholamines including pheochromocytoma.

  6\. The subject is claustrophobic or has a movement disorder that prevents him/her from lying still in a supine position for up to 20 minutes.

  7\. Renal insufficiency (serum creatinine \>3.0 mg/dL). 8. Uses medications that are known to interfere with uptake of NET-dependent agents and these medications cannot be safely withheld 24 hours before study procedures.

  9\. Participated in a research study using ionizing radiation in the previous 12 months such that participation in the study might result in a total effective dose from research procedures exceeding 50 milliSieverts during that time interval.

Where it's running

• Houston Methodist Neurological Institute
  Houston, Texas, United States Recruiting

Study contacts

• Principal investigator: Juan B Toledo, MD — The Methodist Hospital Research Institute
• Study coordinator: Research Coordinator
• Email: Jrrodriguezgaytan@houstonmethodist.org
• Phone: 346-238-2677

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Parkinson’s Risk in Gaucher Disease Type 1

  This study tests how Parkinson’s risk relates to GBA1-related Gaucher disease in adults over 40, by collecting detailed clinical data and samples for future research.

  Recruiting Icahn School of Medicine at Mount Sinai · New York, New York · NCT07886879

• Can the Ronnie Gardiner Method improve thinking and daily function in people with Parkinson’s

  In this 10-week program, adults with Parkinson’s disease will try the Ronnie Gardiner Method to see if it helps thinking, talking, movement, balance, and quality of life.

  Recruiting University Ghent · Ghent, Oost-Vlaanderen · NCT07863219

• Effects of excitatory and inhibitory LIFUS of GPi in Parkinson’s patients without DBS

  This study tests two deep-brain focused ultrasound patterns on people with Parkinson’s to see if they change task performance and tremor, compared with a sham stimulation.

  Recruiting University Health Network, Toronto · Toronto, Ontario · NCT07846007

• Capacitive-resistive radiofrequency therapy for people with Parkinson's disease

  This study tests four TECAR therapy protocols on the legs to see which best reduces muscle stiffness and improves walking in people with Parkinson's disease.

  Recruiting Universidad San Jorge · Zaragoza, Zaragoza · NCT07842926

• TRB-001 safety and immune response in early Parkinson's disease

  This early-phase study tests TRB-001 against placebo to see if it is safe and prompts an immune response in people with recently diagnosed Parkinson’s disease.

  Recruiting Phase 1 Tridem Bioscience FlexCo · Vienna · NCT07840027

• Bayesian optimization to tune DBS for better gait in Parkinson’s patients

  This study tests whether using Bayesian optimization can quickly find DBS settings that lengthen step length in people with Parkinson's who already have DBS in place.

  Recruiting Early Phase 1 University of Minnesota · Minneapolis, Minnesota · NCT07835308

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.